Catalysts for GlaxoSmithKline LLC
412 tracked
Jul 18, 2025
approval
ZEJULA (NIRAPARIB TOSYLATE) — FDA approval
niraparib
→
Jun 18, 2025
approval
ZEJULA (NIRAPARIB TOSYLATE) — FDA approval
niraparib
→
Jun 18, 2025
approval
ZEJULA (NIRAPARIB TOSYLATE) — FDA approval
niraparib
→
Apr 25, 2025
approval
LAMICTAL XR (LAMOTRIGINE) — FDA approval
LAMOTRIGINE
→
Apr 25, 2025
approval
LAMICTAL XR (LAMOTRIGINE) — FDA approval
LAMOTRIGINE
→
Apr 25, 2025
approval
LAMICTAL CD (LAMOTRIGINE) — FDA approval
LAMOTRIGINE
→
Apr 25, 2025
approval
LAMICTAL CD (LAMOTRIGINE) — FDA approval
LAMOTRIGINE
→
Apr 25, 2025
approval
LAMICTAL (LAMOTRIGINE) — FDA approval
LAMOTRIGINE
→
Apr 25, 2025
approval
LAMICTAL (LAMOTRIGINE) — FDA approval
LAMOTRIGINE
→
Apr 25, 2025
approval
LAMICTAL ODT (LAMOTRIGINE) — FDA approval
LAMOTRIGINE
→
Apr 25, 2025
approval
LAMICTAL ODT (LAMOTRIGINE) — FDA approval
LAMOTRIGINE
→
Apr 18, 2025
approval
OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval
momelotinib dihydrochloride
→
Mar 25, 2025
approval
BLUJEPA (GEPOTIDACIN MESYLATE) — FDA approval
gepotidacin mesylate
→
Mar 19, 2025
recall
Aspen Biopharma Labs Pvt., Ltd. recall (Cls II)
GlaxoSmithKline LLC
→
Feb 5, 2025
approval
WELLBUTRIN (BUPROPION HYDROCHLORIDE) — FDA approval
BUPROPION HYDROCHLORIDE
→
Jan 10, 2025
approval
FLONASE SENSIMIST ALLERGY RELIEF (FLUTICASONE FUROATE) — FDA approval
GlaxoSmithKline LLC
→
Oct 24, 2024
approval
FLONASE SENSIMIST ALLERGY RELIEF (FLUTICASONE FUROATE) — FDA approval
GlaxoSmithKline LLC
→
May 7, 2024
approval
WELLBUTRIN (BUPROPION HYDROCHLORIDE) — FDA approval
BUPROPION HYDROCHLORIDE
→
May 7, 2024
approval
WELLBUTRIN SR (BUPROPION HYDROCHLORIDE) — FDA approval
BUPROPION HYDROCHLORIDE
→
Nov 15, 2023
approval
FLONASE SENSIMIST ALLERGY RELIEF (FLUTICASONE FUROATE) — FDA approval
GlaxoSmithKline LLC
→
Sep 15, 2023
approval
OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval
momelotinib dihydrochloride
→
Apr 26, 2023
approval
ZEJULA (NIRAPARIB TOSYLATE) — FDA approval
niraparib
→
Dec 6, 2022
approval
WELLBUTRIN (BUPROPION HYDROCHLORIDE) — FDA approval
BUPROPION HYDROCHLORIDE
→
Dec 6, 2022
approval
WELLBUTRIN SR (BUPROPION HYDROCHLORIDE) — FDA approval
BUPROPION HYDROCHLORIDE
→
Nov 30, 2022
approval
BREXAFEMME (IBREXAFUNGERP CITRATE) — FDA approval
ibrexafungerp citrate
→
Jun 15, 2022
approval
BREXAFEMME (IBREXAFUNGERP CITRATE) — FDA approval
ibrexafungerp citrate
→
Dec 20, 2021
approval
IMITREX STATDOSE (SUMATRIPTAN SUCCINATE) — FDA approval
SUMATRIPTAN SUCCINATE
→
Jun 14, 2021
approval
VALTREX (VALACYCLOVIR HYDROCHLORIDE) — FDA approval
VALACYCLOVIR HYDROCHLORIDE
→
Jun 1, 2021
approval
BREXAFEMME (IBREXAFUNGERP CITRATE) — FDA approval
ibrexafungerp citrate
→
Mar 31, 2021
approval
LAMICTAL XR (LAMOTRIGINE) — FDA approval
LAMOTRIGINE
→